Quick Dispatch:
Your glp-1 roche GLP-1-based therapies for diabetes, obesity and beyond orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1 roche GLP-1-based therapies for diabetes, obesity and beyond ships.
Need Help?
Questions about glp-1 roche GLP-1-based therapies for diabetes, obesity and beyond, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1 roche GLP-1-based therapies for diabetes, obesity and beyond in your area.
![Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://a.storyblok.com/f/176343/1920x1281/9879d12165/roche_270354.jpeg)
Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
25.12
The next wave of GLP-1 medications could make weight management easier — and more personalized — than ever. Drugmakers like Pfizer, Amgen, Eli Lilly, Roche, Structure Therapeutics, and Novo Nordisk are working
20.93
Roche, trailing in obesity, showcases new data for GLP-1 shot
25.19
Roche's Novel Dual GLP-1/GIP Receptor Agonist Produces Clinically Meaningful Weight Loss in Phase Ib Trial
28.66
Roche plans to become top 3 obesity player as CT-388 enters trial
20.65
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial | News
23.25
![Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://a.storyblok.com/f/176343/1920x1281/88773444bc/roche_279855.png)
Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
25.24
